Member Info for Laura2022

There is someone buying them Hull

"Recognised by many regulatory authorities "

Things You Should Know About Virtual Tumour™

 

It’s implemented in MATLAB

An industry standard platform used to develop mathematical models with over 3m users worldwide. Recognised by many regulatory authorities as a validated coding environment.

Very detailed and very positive picture painted of VT's capabilities within oncology

https://www.physiomics.co.uk/virtual-tumour-technology/

Beyond Blood is collaborating with global companies working on similar microfluidic technologies, pushing the boundaries of what their device can do. These advances will benefit rare disease patients and have broader applications for viral infections and other health concerns. Their work has been recently featured on the Imperial College website, and they have received funding from the Canadian National Research Council for a joint project with the NRC’s Nanotechnology Research Centre to develop a circulating tumour cell isolation and detection point of care device.

And this is just the beginning. Beyond Blood’s ultimate dream is to develop a wearable or implantable device that continuously monitors a patient’s health without any intervention. This could be a game-changer for patients living with conditions such as Alzheimer

Blog 30th Sept 2024

The Power of Collaboration: Beyond Blood

by Georgie | Sep 30, 2024 | Collaboration, RAREfest, Technology | 0 comments

77/ 100

A Budding Entrepreneur, an Engaged Rare Disease Community, and a Transformative New Device.Have you or someone you care for with a rare condition needed blood tests recently? Now, imagine a world where checking your health is as simple as making a cup of tea—no hospital visits, no waiting rooms, and no needles. This is the future Beyond Blood Diagnostics is creating.

 

Founded in 2022 by Manfredi San Germano, Beyond Blood Diagnostics is developing a revolutionary at-home blood-testing device that could redefine healthcare, especially for those living with chronic and rare conditions. This device promises to be portable, easy to use, pain-free, and quick, delivering reliable blood test results in less than 15 minutes—all from a simple finger prick. The team’s patented technology harnesses cutting-edge AI and microfluidic chips, allowing users to get a full blood count (FBC) at home, providing insights that could diagnose infections, neutropenia, anaemia, and more.

Beyond Blood’s journey from an innovative idea to a promising tech solution is one powered by community engagement, particularly with the rare disease community. The rare disease community’s role in shaping and guiding this product has been instrumental. And now, this exciting partnership is headed to RAREfest24, where Beyond Blood will showcase its prototype—a true testament to the power of collaboration and consultation.

Beyond Blood: A Vision to Revolutionise At-Home Blood Testing

Manfredi San Germano is no stranger to life sciences innovation. With a background in commercialising genomic tests and a PhD in Biomedical Engineering from Imperial College London, Manfredi’s expertise in microfluidic applications in medicine set the stage for Beyond Blood’s inception. His belief? The next frontier of patient care lies in empowering people to monitor their health at home.

Beyond Blood’s device is designed to allow patients to conduct full blood counts—a critical test for monitoring a range of health conditions—without the need for labs. This innovation promises convenience, cost savings, and, above all, control over one’s health. And it’s not just for the general population; Beyond Blood is particularly attuned to the needs of the rare disease community, who often face unique and complex challenges in healthcare.

Why the Rare Disease Community?

Over 3.5 million people worldwide live with rare diseases, with around 40% experiencing haematological co-morbidities. Blood health plays a crucial role in diagnosing and managing rare conditions, but frequent trips to the lab for tests can add yet another burden to an already difficult healthcare journey. This presented an opportunity for Manfredi: if blood tells us so much about a person’s health, offering a portable, user-fr

Physiomics and Beyond Blood are, in addition, exploring joint grant applications and considering other ways in which Physiomics' software could be used alongside Beyond Blood's devices. It is anticipated that the analysis of data generated by Beyond Blood's diagnostic platform will take place over the course of the balance of this calendar year and further updates will be provided in due course.

Beyond Blood Diagnostics is developing a revolutionary at-home blood-testing device that could redefine healthcare, especially for those living with chronic and rare conditions. This device promises to be portable, easy to use, pain-free, and quick, delivering reliable blood test results in less than 15 minutes—all from a simple finger prick. The team’s patented technology harnesses cutting-edge AI and microfluidic chips, allowing users to get a full blood count (FBC) at home, providing insights that could diagnose infections, neutropenia, anaemia, and more.

Well worth reading the full blog at the bottom of the 10.15am post from KingH

The Power of Collaboration: Beyond Blood

by Georgie | Sep 30, 2024 | Collaboration, RAREfest, Technology | 0 comments

77/ 100

A Budding Entrepreneur, an Engaged Rare Disease Community, and a Transformative New Device.Have you or someone you care for with a rare condition needed blood tests recently? Now, imagine a world where checking your health is as simple as making a cup of tea—no hospital visits, no waiting rooms, and no needles. This is the future Beyond Blood Diagnostics is creating.

 

Founded in 2022 by Manfredi San Germano, Beyond Blood Diagnostics is developing a revolutionary at-home blood-testing device that could redefine healthcare, especially for those living with chronic and rare conditions. This device promises to be portable, easy to use, pain-free, and quick, delivering reliable blood test results in less than 15 minutes—all from a simple finger prick. The team’s patented technology harnesses cutting-edge AI and microfluidic chips, allowing users to get a full blood count (FBC) at home, providing insights that could diagnose infections, neutropenia, anaemia, and more.

Beyond Blood’s journey from an innovative idea to a promising tech solution is one powered by community engagement, particularly with the rare disease community. The rare disease community’s role in shaping and guiding this product has been instrumental. And now, this exciting partnership is headed to RAREfest24, where Beyond Blood will showcase its prototype—a true testament to the power of collaboration and consultation.

Beyond Blood: A Vision to Revolutionise At-Home Blood Testing

Manfredi San Germano is no stranger to life sciences innovation. With a background in commercialising genomic tests and a PhD in Biomedical Engineering from Imperial College London, Manfredi’s expertise in microfluidic applications in medicine set the stage for Beyond Blood’s inception. His belief? The next frontier of patient care lies in empowering people to monitor their health at home.

Beyond Blood’s device is designed to allow patients to conduct full blood counts—a critical test for monitoring a range of health conditions—without the need for labs. This innovation promises convenience, cost savings, and, above all, control over one’s health. And it’s not just for the general population; Beyond Blood is particularly attuned to the needs of the rare disease community, who often face unique and complex challenges in healthcare.

Why the Rare Disease Community?

Over 3.5 million people worldwide live with rare diseases, with around 40% experiencing haematological co-morbidities. Blood health plays a crucial role in diagnosing and managing rare conditions, but frequent trips to the lab for tests can add yet another burden to an already difficult healthcare journey. This presented an opportunity for Manfredi: if blood tells us so mu

Interesting observations and replies

Thankyou all

Merging with main market would make sense although later in article it says that AIM has worked for 30yrs but needs rejuvenating

New investment deals

Some of the new investment pledges from firms on Monday include:

£279m from US pharmaceutical giant Eli Lilly to tackle "significant health challenges", such as obesity

Prime Minister Starmer has highlighted is attracting more investment in biosciences and life sciences businesses to the UK.

5.1mln at 0 22p

Yeah

You can pick them all by yourself with HEMO NEO etc

X

Today (14th October) the newly-installed Labour government makes its first attempt to lance the boil that has dogged the UK economy for nearly two decades – a lack of investment. According to the OECD, the last time the UK was above the G7 median level of investment as a proportion of GDP was in 1990. Business investment is lower in the UK than any other country in the G7.

That is why today’s investment summit in the Guildhall, London is so important for the government’s long-term economic plans, and one of the priorities that Prime Minister Starmer has highlighted is attracting more investment in biosciences and life sciences businesses to the UK. However, the UK is none-too-shabby in the field of biotech and life sciences, boasting global titan, AstraZeneca LON:AZN, one of the world’s leading pharmaceutical companies and Oxford Nanopore LON:ONT, renowned for its cutting-edge DNA sequencing technologies

Great news given the press coverage 2 weeks ago on BBC about the funding for cancer tests in the UK

What has happened ?

There is no RNS

Kong

I'm relaxed as I'm in at 3.2p and can add more here if needed

There are approximately 2,000 concierge clinics in the US which converts to an addressable market for this segment of circa 150,000 cash-pay tests per annum.  

In addition, we have been reimbursed for PSE tests under our existing CPT/PLA code (0433U) by several US insurers including Humana, UHC, Medicare and Optum Health. In the UK, sales of the test have come through the Company's partnership with the Goodbody Clinic and from private clinics such as The London Clinic.

PSE has received a high level of attention within the industry because of its accuracy and ease of use. This has led to ongoing discussions with two of the leading diagnostic services companies in the US for a distribution deal that would widen access to the test and have the potential to add significant volume.

I would say that BOD taking 25% and CEO 35% in shares is good albeit 2yrs too late

Korg

I wasn't buying at 15-20p+